Compare BLFS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | TBPH |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 824.9M |
| IPO Year | 2013 | 2013 |
| Metric | BLFS | TBPH |
|---|---|---|
| Price | $20.30 | $16.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $18.40 |
| AVG Volume (30 Days) | ★ 328.6K | 301.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.27 | ★ 279.13 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | $15,386,000.00 |
| Revenue This Year | $19.73 | $8.46 |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,049.50 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $9.10 |
| 52 Week High | $29.57 | $21.03 |
| Indicator | BLFS | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 45.74 |
| Support Level | $19.71 | $16.14 |
| Resistance Level | $20.47 | $17.21 |
| Average True Range (ATR) | 0.95 | 0.39 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 17.85 | 11.83 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.